Amentum vs Concentrix
AMTM and CNXC side by side, both in miscellaneous business services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How AMTM and CNXC compare
Amentum is the larger company, worth 2.7 times as much as Concentrix ($5.4B against $2.0B).
Amentum grew revenue faster over the last twelve months (11.4% versus 2.6% for Concentrix).
Amentum keeps more of each dollar of sales as profit, with a net margin of 1.4% compared with −24.0% at Concentrix.
Concentrix pays a dividend yielding 4.4%; Amentum does not pay one.
Amentum scores higher on the StockData Score (9 against 8 for Concentrix), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | AMTM | CNXC |
|---|---|---|
| Size and price | ||
| Market cap | $5.4B | $2.0B |
| Share price | $21.95 | $32.72 |
| Change, 1 year | −4.4% | −7.4% |
| Change, 5 years | – | −82.4% |
| Beta (5Y) | 1.21 | 1.02 |
| Employees | 50K | 455K |
| StockData Score | ||
| Total score | 9 (better) | 8 |
| Valuation score | 4 (better) | 3 |
| Growth score | 3 (better) | 1 |
| Performance score | 1 (better) | 0 |
| Health score | 1 | 1 |
| Dividend score | 0 | 3 (better) |
| Valuation | ||
| P/E | 26.4× | – |
| P/S | 0.4× | 0.2× (better) |
| P/B | 1.1× | 1.1× (better) |
| EV/EBITDA | 14.8× | – |
| P/FCF | 11.3× | 3.5× (better) |
| FCF yield | 8.8% | 28.8% (better) |
| Fair value | $27.54 | $98.17 |
| Margin of safety | 20.3% | 66.7% (better) |
| Growth | ||
| Revenue growth (TTM) | 11.4% (better) | 2.6% |
| Revenue growth, 5Y average | – | 15.8% |
| Net income growth (TTM) | 292% (better) | −856% |
| EPS growth (TTM) | 113% (better) | −921% |
| Profitability | ||
| Gross margin | 10.2% | 34.1% (better) |
| Operating margin | 4.2% (better) | −20.9% |
| Net margin | 1.4% (better) | −24.0% |
| FCF margin | 3.4% | 5.8% (better) |
| Return on equity | 4.5% (better) | −78.2% |
| Return on invested capital | 5.5% (better) | −22.3% |
| Financial health | ||
| Debt / equity | 0.81 (better) | 2.47 |
| Net debt / EBITDA | 5.65 | – |
| Current ratio | 1.52 (better) | 1.23 |
| Altman Z-score | 2.02 (better) | 0.39 |
| Piotroski F-score | 6 (better) | 4 |
| Dividends and buybacks | ||
| Dividend yield | – | 4.4% |
| Buyback yield | – | 5.0% |
| Shareholder yield | 0.00% | 9.4% (better) |
| Ownership | ||
| Held by institutions | 89.6% | 112% |
| Held by insiders | 32.3% | 13.1% |
| Insider net buying, 12 months | – | −$133M |
| Superinvestors holding | 1 | 1 |
| Short interest, % of float | 8.5% | 15.1% |
Go deeper
- AMTM stock overview
- AMTM income statement
- AMTM valuation and score
- CNXC stock overview
- CNXC income statement
- CNXC valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.